Axonics Modulation Technologies (NASDAQ:AXNX) is scheduled to announce Q4 earnings results on Wednesday, March 1st, after market close. The consensus EPS Estimate is -$0.22 (+35.3% Y/Y) and the ...

Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 5.09MM shares of Axonics Modulation Technologies Inc (AXNX). This represents 10.28% of the company. In ...

Weighted-average shares used to compute basic and diluted net loss per share ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating ...

As of March 24, 2023, the average one-year price target for Axonics Modulation Technologies is $84.09. The forecasts range from a low of $65.65 to a high of $94.50. The average price target represents ...

Irvine-based medical device maker Axonics Modulation Technologies Inc. is beefing up plans for going public. The 5-year-old company, which makes electrical stimulation devices designed to treat ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $2.67 per share a year ago.